$CURR News: CURE Pharmaceutical Schedules Investor Webcast for Thursday, May 27, 2021
CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time.
Rob Davidson, CEO of CURE Pharmaceutical Holding (OTCQB: CURR), Nancy Duitch, CEO of wholly-owned subsidiary The Sera Labs and Chief Strategy Officer for the Company, and management from both the pharmaceutical and wellness verticals will present the company’s future positioning and current 2021 accomplishments, as well as answer shareholder questions submitted prior to the webcast. To register for this webcast, please use the below web link.
https://zoom.us/webinar/register/WN_ApUsUmrySOWRTiX2ZPWI1g
If you have questions, please send an email to investor@curepharma.com with ‘CURR Question’ in the subject line by 6 p.m. Eastern Daylight Time on Wednesday, May 26. The executives will answer as many questions as time will allow. For those unable to participate in the live webcast, an archived version of the webcast will be available on the investor relations section of the company's website in the following days.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005375/en/
CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, today announced that it will hold a webcast with the investment community on Thursday, May 27, at 5 p.m. Eastern Daylight Time.
Rob Davidson, CEO of CURE Pharmaceutical Holding (OTCQB: CURR), Nancy Duitch, CEO of wholly-owned subsidiary The Sera Labs and Chief Strategy Officer for the Company, and management from both the pharmaceutical and wellness verticals will present the company’s future positioning and current 2021 accomplishments, as well as answer shareholder questions submitted prior to the webcast. To register for this webcast, please use the below web link.
https://zoom.us/webinar/register/WN_ApUsUmrySOWRTiX2ZPWI1g
If you have questions, please send an email to investor@curepharma.com with ‘CURR Question’ in the subject line by 6 p.m. Eastern Daylight Time on Wednesday, May 26. The executives will answer as many questions as time will allow. For those unable to participate in the live webcast, an archived version of the webcast will be available on the investor relations section of the company's website in the following days.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005375/en/
